QLife

Terms for warrants series TO 4 in brief:

• The exercise price is SEK 0.02 per share.
• The exercise period runs from 7 - 21 June 2024.
• Each warrant entitles the holder to subscribe for one (1) share. Upon exercise of all 1,048,696,624 outstanding warrants, 1,048,696,624 shares will be issued.
• If the warrants are fully exercised, the Company will receive approximately MSEK 21.0 before issue costs.
• Upon full exercise of all warrants, the number of shares in Qlife will increase with 1,048,696,624 to 5,685,729,046 shares, and the share capital will increase with SEK 3,932,612.34 to SEK 21,321,483.9225.
• The outcome is planned to be announced on June 25, 2024.

In total, Qlife issued 131,087,078 units in the Rights Issue, each unit consisting of twenty-three (23) shares, eight (8) warrants series TO 4 and eight (8) warrants series TO 5. One (1) warrant series TO 4 entitles the holder to subscribe for one (1) new share in the Company during the period 7 - 21 June 2024 at an exercise price of SEK 0.02 per share and one (1) warrant series TO 5 entitles the holder to subscribe for one (1) new share in the Company during the period 21 November - 5 December 2024 at an exercise price of SEK 0.0225 per share.

In the event of full exercise of all warrants of series TO 4, the Company will receive approximately MSEK 21.0 before issue costs. In order for the warrants not to expire and lose their value, they must be actively sold by 18 June 2024 at the latest, or be exercised no later than 21 June 2024.

Note that warrants that have not been actively sold by 18 June 2024 at the latest, or been exercised no later than 21 June 2024, will expire and lose their value.

Exercise of warrants series TO 4

Trustee-registered warrants

If the warrant holder holds warrants in a deposit account, in an investment savings account or endowment insurance (trustee-registered holdings), subscription and payment will take place with the trustee, which will provide further instructions on how to exercise the warrants. The warrant holder should contact their trustee well in advance for further instructions regarding exercise of the warrants.

Directly registered warrants (securities account)

Directly registered warrant holders can order an application form via info@eminova.se or by phone on +46 8-684 211 00. Payment is made in accordance with the instructions in the application form. Both the application form and payment must be submitted to Eminova Fondkommission AB by 15.00 CEST on 24 June 2024 at the latest.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34